Pharvaris (NASDAQ:PHVS) Insider Anna Nijdam Sells 2,670 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 2,670 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total transaction of $82,422.90. Following the transaction, the insider directly owned 46,275 shares of the company’s stock, valued at approximately $1,428,509.25. This trade represents a 5.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The stock was sold at an average price of $30.60, for a total transaction of $55,967.40.
• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total transaction of $169,100.74.

Pharvaris Stock Up 1.6%

Pharvaris stock opened at $31.59 on Tuesday. Pharvaris N.V. has a 52-week low of $16.00 and a 52-week high of $33.33. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -9.93 and a beta of -2.35. The firm has a 50-day moving average price of $29.32 and a two-hundred day moving average price of $27.37.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. Research analysts expect that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on PHVS shares. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday. UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Citizens Jmp reduced their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of Pharvaris during the 4th quarter worth about $35,000. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris during the third quarter worth about $75,000. Barclays PLC acquired a new stake in Pharvaris during the fourth quarter worth about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris during the fourth quarter valued at about $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.